New Issue: Orbital Catastrophe Ahead? Read Now

Nanoparticles Annihilate Prostate Cancer

Join Our Community of Science Lovers!

Fighting cancer is currently a messy war. Modern chemotherapies attack tumors with the equivalent of a machinegun approach: cover the area widely with deadly fire and hope to destroy the tumor with a minimum of collateral damage. Doctors have long sought a way to precisely target tumors with their chemical therapies. Now researchers may have found it in a nanoparticle laced with a cancer-combating drug.

Omid Farokhzad of Harvard University, Robert Langer of the Massachusetts Institute of Technology and their colleagues created the nanoparticle out of a previously FDA-approved polymer that has been shown to dissolve inside cells. This nanoparticle--one-thousandth the width of a human hair--carries a load of a lethal chemical: docetaxel, which is currently used to treat prostate cancer. In addition, the scientists studded the outside of the particle with so-called aptamers--tiny proteins that link directly to cancer cells while avoiding regular cells. Finally, they equipped the nanoparticles with polyethylene glycol molecules, which allow them to resist the internal defenses of a tumor cell.

In both laboratory dishes and mice with human prostate cancers, the nanoparticles proved extremely effective. "A single injection of our nanoparticles completely eradicated the tumors in five of the seven treated animals and the remaining animals had significant tumor reduction compared to the controls," Farokhzad says.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


In fact, the mice that received the complete nanomedicine package had smaller tumors and longer lifespans than their counterparts injected with saline, nanoparticles without the drug, the drug alone, and nanoparticles with the drug but without the targeting aptamers. The research appears online this week in the Proceedings of the National Academies of Science.

Further tests will be needed to ensure that the nanoparticle is safe in animals and, eventually, in humans afflicted with prostate cancer. The technique may even find wider application. "[Researchers] can put different things inside or other things on the outside of the nanoparticles. In fact, this technology could be applied to almost any disease," Farokhzad argues. And that may prove the advent of a little more rifle-like precision in the war on cancer.

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American

Subscribe